Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that two abstracts will be published at the American Society of Clinical Oncology (ASCO) 2020 Virtual Meeting to be held from May 29 to May 31.
If you own shares in Tyme Technologies, Inc. (NASDAQ:TYME) then it's worth thinking about how it contributes to the...
Two music titans—one old, one young—snuck out new songs in the past month. In headline form, the news is that Bob Dylan is writing songs about dying and Beyonce is consolidating her credibility as a rapper. Upon longer listen, however, Dylan’s “Murder Most Fo…
They have a low financial burden ,which decreases bankruptcy risk Continue reading...
Former World Wrestling Entertainment star Shad Gaspard was found dead Wednesday on a Los Angeles beach after going missing in a swimming accident over the weekend, authorities said. He was 39. The Los Angeles County Medical Examiner-Coroner’s office confirmed…
As the sports entertainment world continues to reel from the death of former WWE superstar Shad Gaspard, an anonymous donation is pointing to one person.
EGRX earnings call for the period ending March 31, 2020.
Someone donated $40,000 to the family of the late WWE star Shad Gaspard ... and it's looking like the secret donor is none other than John Cena. The family created a GoFundMe account for funeral and other expenses ... this after Shad tragically…
Shad Gaspard, former WWE wrestler and member of tag team Cryme Tyme, has gone missing after swimming with his son in Marina Del Rey Beach on Sunday afternoon, but an official working with the L.A. Fire Dept. told media they believe the 39-year-old "did submer…
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 2020 Cross-Border Healthcare Webinar Series on Tuesday, April 7, 2020. The Company will present its corporate overview with a focus on:
JTG (Jayson Anthony Paul) tweeted an emotional tribute to his longtime tag team partner Shad Gaspard, who died after being caught in a riptide while swimming with his son in Venice Beach, California, earlier this month...
Former WWE Superstar Shad Gaspard went missing off the coast of Venice Beach.
Strategic collaboration with Eagle Pharmaceuticals entitles TYME to receive up to a total of $40 million, which included $20 million upfront already received and $20 million in.
Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.
The pro wrestling world lost one of its best. Shad Gaspard, 39, died after being caught in a riptide in California and telling lifeguards to save his son.
The wife of actor and former WWE star Shad Gaspard, who disappeared after saving his son from rough waves on a California beach, has begged fans on social media to help find the 6ft 7in giant as rescue teams continue their search. Read Full Article at RT.com
Shad Gaspard, former WWE wrestler and member of tag team Cryme Tyme, has gone missing after swimming with his son in Marina Del Rey Beach on Sunday afternoon, but an official working with the L.A. Fire Dept. told media they believe the 39-year-old "did submer…
As the search for Shad Gaspard continues, Mark Kriegel reflects on his friend's legacy and the bond between father and son that defined him.
Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 2019 Cross-Border Healthcare Winter Summit on Tuesday, December 10, 2019. The Company will present its corporate overview for 2019 with a special focus on growth opportunities driven by advances in the science of cancer metabolism, recently launched pivotal trial in pancreatic cancer and expanding clinical plans for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate, sarcoma, breast and hematological cancers. Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.
Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the Company will host a conference call and live webcast on Wednesday, May 20, 2020 at 5:00 P.M. ET to report its financial and operating results for its fourth quarter and fiscal year ended March 31, 2020. TYME delivered on multiple major milestones in Fiscal Year 2020, including the highest corporate priority to launch its first pivotal trial that will evaluate oral SM-88 (racemetyrosine) for patients with third-line pancreatic cancer. TYME is now one important step closer to becoming a commercial enterprise.
In honor of music executive Andre Harrell's passing, Billboard compiled ten essential records that made Uptown Records a force in the late '80s and early '90s.
Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the first pancreatic cancer patient has been dosed in Part 2 of the TYME-88-Panc pivotal trial designed to support approval of SM-88 (racemetyrosine) for the third-line treatment of patients with metastatic pancreatic cancer. CMBTs are proprietary investigational compounds that are believed to disrupt cancer cells’ protein synthesis, leading to a breakdown of the cancer’s key defenses and cell death.
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced the results of a health economic outcomes study demonstrating that the therapeutic benefit of increasing the use of novel medicines is so great that it is driving a decrease in the actual total cost of healthcare. Health technology assessment programs are increasingly using real-world patient data to assess the effect of new medicines on total cost of care. This study analyzed such data to measure the impact of new pancreatic cancer therapies on other non-therapeutic medical expenditures.
WWE is saddened to learn of the passing of Shad Gaspard.
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present a corporate overview for 2020 at BIO Digital from June 8-12. For 2020, the BIO International Convention has transitioned to a new, virtual event format. The Company will present its corporate overview for 2020 with a special focus on multiple growth opportunities driven by advances in the science of cancer metabolism, pivotal trial in pancreatic cancer, clinical trial in ultra-rare metastatic sarcoma and expanding clinical plans for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate, breast and/or hematological cancers.
Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that leadership will participate at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020. The Company will present its corporate overview for 2020 with a special focus on multiple growth opportunities driven by advances in the science of cancer metabolism, pivotal trials in pancreatic cancer, clinical trial in ultra-rare metastatic sarcoma and expanding clinical plans for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate, breast and hematological cancers.
NEW YORK, NY / ACCESSWIRE / May 20, 2020 / Tyme Technologies, Inc. (NASDAQ:TYME) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on May 20, 2020 at 5:00 ...
Tyme (TYME) is evaluating its lead cancer candidate, SM-88, as third-line treatment for metastatic pancreatic cancer in a pivotal study.
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced preliminary financial and operating results for its fourth quarter and fiscal year ended March 31, 2020. TYME delivered on multiple major milestones in Fiscal Year 2020, including its two most important corporate priorities, launching the first pivotal trial that will evaluate oral SM-88 (racemetyrosine) for patients with third-line pancreatic cancer and strengthening its capital structure. Given these developments, TYME now has a clear path toward becoming a commercial enterprise.
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that two posters will be presented at the American Association for Cancer Research (AACR) 2020 Virtual Meeting to be held from June 22 to June 24, 2020.
Iconic music executive Andre Harrell passed away at the age of 59. We remember his life and legacy as an innovator who shifted culture.
Penny stocks offer a conundrum for the investor; The low valuation scares the cautiously inclined away due to the cheap nature of the stock. On the other hand, they represent incredible opportunity for the risk tolerant amongst us. Invariably, this almost "catch 22" like situation begs the question: why are these companies priced so low? Is it due to bad fundamentals, indicating stocks that aren’t worth pursuing? Or is it that the market is missing something and there is opportunity to pick up a winner at a ridiculously low price?A bit of both, possibly. There is no doubt, though, that while a penny stock might represent the road to majestic returns, it is also inherently riskier, increasing the possibility of losing your hard-earned cash.So, how to find which are the penny stocks to invest in, then? TipRanks’ Stock Screener comes in handy here. The tool identified for us three micro-cap stocks that have taken a beating in the past year, but which the people in the know think are ready for some upside action in 2020. Additionally, all three currently have a Strong Buy consensus rating. Let’s check them out.KushCo Holdings (KSHB)KushCo sells ancillary goods & services to the global cannabis industry, mostly vaping related products. The cannabis industry as a whole has had a torrid 2019; The industry has struggled on various fronts, including supply problems and regulatory issues.The company, in this instance, is even further exposed, as vaping related “mystery lung” illnesses and even deaths have surfaced this year, raising the alarm bells on the safety of vaping products. Since then, the reason for the illnesses has been identified as vitamin E acetate found in less rigorously tested vaping products which are sold on the black market.While the industry is not completely out of the woods just yet, eventually, in a market still finding its feet, the companies with strong fundamentals are likely to kick off the dust and rise again. Jefferies’ Owen Bennett believes KSHB is one such company. The analyst said, “Despite an attractive sales profile vs NA cannabis peers, operating in a federally legal way in the US (can be national/list on a major exchange), and with strong barriers to entry, it's valuation is one of the cheapest. With current multiple headwinds set to unwind (particularly on vapour), and additional positive catalysts likely, we see significant re-rating potential the next 12-24 months.”To this end, Bennett rates KushCo shares a Buy along with a $3 price target, which represents over 130% upside potential. (To watch Bennett’s track record, click here)Does the Street reckon the cannabis product manufacturer will blow the smoke away to rise again? Yes, it does. A Strong Buy analyst consensus rating breaks down into 4 Buy ratings with no Holds or Sells. The average price target of $4.33, even outstrips Bennet’s bullish thesis, and indicates high upside potential of 203%. (See KushCo price targets and analyst ratings on TipRanks)Sesen Bio (SESN)Sesen Bio shareholders have had a rough 2019, as Mr. Market chopped off nearly 30% of the company’s stock price. However, 5-star Canaccord analyst John Newman thinks this new, lower stock price could offer new investors an opportunity to get into SESN on the cheap. The analyst reiterated a Buy rating on Sesen, alongside a price target of $5, implying potential upside of a blockbusting 405%. (To watch Newman’s track record, click here)Sesen’s modus operandi is the fight against cancer with the development of fusion protein medicines. The biotech’s lead candidate is Vicinium, a treatment for bladder cancer. The drug is currently in a Phase 3 trial, and Sesen recently initiated its Biologics License Application (BLA) for Vicinium with the FDA. Once the company receives acknowledgement of the BLA, it will begin planning ahead for its ODAC (Oncology Drugs Advisory Committee), currently expected to take place in 2020.With the confirmatory study for Vicinium in its sight, Newman believes there is “opportunity for label expansion.” The top analyst said, “We believe Sesen's confirmatory trial could show superiority vs control in NMIBC (non-muscle invasive bladder cancer), boosting usage among urologists and strengthening reimbursement from insurers. In addition, expanding to inadequate BCG dosed patients should broaden the market opportunity from BCG-intolerant patients, a potential positive… We continue to expect the ODAC for Vicinium to be positive, especially in light of a continued BCG (Bacilus Calmette Guérin) shortage, and believe the panel will vote in favor of Vicinium's favorable benefit/risk profile.”Two other analysts have chipped in with a view on the biotech’s prospects over the last 3 months. All are vocal in their support and rate the stock a Buy. Therefore, Sesen has a Strong Buy consensus rating. The average price target is $3.42 and indicates possible huge gains of 227% in the coming year. (See Sesen stock-price forecast on TipRanks)Tyme Technologies (TYME)Time hasn’t been kind to biotech Tyme Technologies; 2019 has continued a multi-year trend and has been a bit of a letdown, to say the least. Since the turn of the year this beaten down stock has shed more than 70% of its value. That, according to some optimistic analysts, could be about to change.Tyme is a fellow company focused on cancer cures. Its lead candidate is SM-88, currently in Phase 2 development for pancreatic and prostate cancer. Earlier this year, Tyme presented encouraging data from the trial at ESMO (european society for medical oncology) and Evercore’s Joshua Schimmer has been assessing the results.The 5-star analyst believes that “significant unmet need remains in pancreatic cancer.” He said, “Aggregate 5-year survival rate for metastatic pancreatic cancer is only 9%, and recent oncology advancements have failed to be effective in this tumor. We estimated a market size for 3L alone of >$500M, and penetration into earlier lines of therapy would broaden peak sales… While obviously not without risk, especially in pancreatic cancer, SM-88 has shown broad anti-tumor activity in early clinical studies, physician feedback has been strong, and upside should the product succeed is substantial.”Accordingly, Schimmer reiterated an Outperform rating on Tyme, alongside a price target of $7. Should the target be met, investors could be lining pockets with an incredible 566% gain over the next 12 months. (To watch Schimmer’s track record, click here)The Street is rather quiet right now, in regard to Tyme’s prospects. Only two other analysts have recently thrown the hat in with a view on the biotech, both giving it the thumbs up. Tyme’s Strong Buy consensus rating comes with an average price target of $8.50. which implies incredible upside of 721%. (See Tyme price targets and analyst ratings on TipRanks)
The biggest night of All Elite Wrestling 's year arrived Saturday at Daily's Place in Jacksonville, Florida, with Double or Nothing, the one-year anniversary of the revolutionary ...
Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the first sarcoma cancer patient has been dosed at the Sarcoma Oncology Center in the HopES Phase II trial designed to evaluate SM-88 (racemetyrosine) for the treatment of high-risk sarcomas, which are ultra-rare cancers with high unmet medical need. CMBTs are proprietary investigational compounds that are believed to disrupt cancer cells’ protein synthesis, leading to a breakdown of the cancer’s key defenses and cell death.